By working directly from primary sequence data, it eliminates the need for external 3-D structure-prediction software and other open-source packages. Instead, our technology performs ultra-high-throughput virtual screening and multi-objective optimisation, evaluating up to 10¹⁰ candidates within hours to days—giving our partners capabilities that off-the-shelf tools cannot match.
SentinusAI® is a de novo antibody and fusion protein engineering AI platform that designs and optimizes candidates based solely on the target sequence, delivering computational results within a week and optimized drug candidates within a month. Milestone success is typically achieved with wet-lab testing of just 50–150 protein molecules across 3 iterations.
IgG, Fab, scFv, VHH, peptides etc.
Bispecific and multi-specific formats
Antibody-drug conjugate (ADC, PDC)
Therapeutic Antibody Affinity Maturation
Fusion Protein Engineering
Immunogenicity Assessment
Antibody Humanization
Binding specificity Optimization
Protein Off-target Toxicity Prediction
Stability Prediction of Sequence
Optimization
CarbonAI® is a de novo small-molecule and PROTAC AI design engine capable of screening billions of compounds in mere days, simultaneously optimizing multiple pharmacological properties for lead generation and optimization. It delivers 50 candidates in 3 iterations for wet-lab testing, with milestone success achieved.
Scaffold Hopping de novo Generation
Lead Optimization Analog Expansion
PROTAC de novo Generation
ADME(Absorption, Distribution, Metabolism, Excretion) Prediction
Toxicity Prediction
DMPK Prediction
Protein Binding Specificity Optimization
Target Binding Pocket Detection
Molecular Docking
Compound Off Target Toxicity Prediction
CellulaAI™ represents a cutting-edge AI system that leverages the power of artificial intelligence to transform CAR-T therapy. By optimizing every aspect of the CAR-T design and production process, this engine aims to bring safer, more effective, and personalized cancer treatments to patients worldwide. We can design binder targeting multiple cell specific antigen groups simultaneously. We can design binding molecules that simultaneously target multiple cell-specific antigen groups, including patient-specific neoantigens derived from tumor sequencing results, to achieve personalized cell therapy.
